Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Biohaven Pharmaceutical Stock Fell as Much as 28.6% Today

By Maxx Chatsko - Oct 2, 2017 at 12:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A lead product candidate failed in a phase 2/3 trial, but shares have recovered to a smaller loss.

What happened

Shares of pre-revenue biopharma Biohaven Pharmaceutical (BHVN 0.10%) dropped nearly 29% this morning after the company reported that one of its lead drug candidates failed to meet both its primary endpoint and key secondary outcome measure in a phase 2/3 trial. The drug candidate, trigriluzole, was the most advanced in the company's glutamate platform, which targets several rare diseases. The other drug platform is taking aim at more effective treatments for migraines

Although the drug candidate was well-tolerated, it failed to beat placebo in a trial investigating the potential to treat spinocerebellar ataxia, a severe and often fatal genetic disease affecting motor function. There is no effective treatment nor cure for the hereditary disease. 

Shares recovered quickly after a precipitous drop shortly after market open. As of 12:13 p.m. EDT, the stock had settled to a 12.9% loss.

A businessman holding out a flat hand with a declining bar chart hovering over it, showing losses.

Image source: Getty Images.

So what

Biohaven Pharmaceutical reported that the drug candidate underperformed placebo on the primary endpoint of average change from baseline on the scale for the assessment and rating of ataxia after eight weeks of treatment. Trigriluzole demonstrated an improvement of -0.81 points on the scale, compared to -1.05 points for patients taking a placebo. The difference was not significant.

The key secondary outcome measure was patient's global impression of change, in which patients were asked how they felt and if they thought their conditions had improved over the course of treatment. Only 50.8% of patients taking the drug candidate thought the therapy helped, compared to 59.1% who felt their condition had improved and were taking placebo. The company noted that it thought the placebo response was surprisingly strong in this particular trial.

The trial failure is a blow to Biohaven Pharmaceutical for more than the immediately obvious reasons. Trigriluzole is being evaluated as a treatment for other ataxias (Friedreich's ataxia and sporadic ataxia), which are near the middle of their development. If the drug candidate fails to be an effective treatment for these hereditary diseases, then that wipes away half of the company's pipeline for its glutamate platform.

Now what

Drug failures are par for the course when it comes to treating rare diseases -- the only type of illnesses the company's glutamate platform targets. That said, Biohaven Pharmaceutical has a much less risky drug platform developing treatments for migraines. In 2017 it started two phase 3 trials for its lead drug candidate in that platform, which are expected to produce top-line results in the first half of 2018. That may explain why shares recovered so sharply today, as investors may have something to look forward to. However, as a pre-revenue company, this stock remains a speculative bet.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biohaven Pharmaceutical Holding Company Ltd. Stock Quote
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$147.76 (0.10%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.